Medinet (2370) · InitiativeAdvancedLatest Revision of earnings forecasts (2026-10-16): "Cited as achieved"
Contract Manufacturing of S-DSC® Using Technology Provided by Shiseido Company,Limited
First written in FY2025-H1. 3 of 5 entries say "Advanced", first in FY2025. Latest entry: 2026-10-16.
5entries
2years
3from disclosures
How it moved
Same theme, other companies
Launch of a Regenerative Medicine CDMO and Contract Cell Manufacturing BusinessA theme 13 companies write about · 1 as a headwind · 20 as a tailwind
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
0 other companies' latest entry also says "Cited as achieved".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2025AdvancedAnnual report
「In the specific cell-processed products manufacturing business, the number of cell-processing cases for immune cells and S-DSC®, using technology provided by Shiseido Company,Limited, was below the initial forecast, among other factors.」
While continuing contract manufacturing of S-DSC® using technology provided by Shiseido Company,Limited, the number of cell-processing cases during the fiscal year was below the initial forecast. - FY2025-H1First statedAnnual report
「Revenue from the start of contract manufacturing of S-DSC®, using technology provided by Shiseido Company,Limited, which began in the previous year, was recognized from the beginning of the interim accounting period.」
Contract manufacturing of S-DSC® using technology provided by Shiseido Company,Limited began in the previous year, and revenue was recognized from the start of the interim accounting period.